Key Takeaways Results from a late-stage trial of Eli Lilly’s experimental weight loss pill were disappointing, sending shares of the drugmaker tumbling. The study found average weight loss from the treatment was below that of rival Novo Nordisk’s Wegovy. The news offset Lilly’s much better-than-expected quarterly results and guidance boost. Ely Lilly (LLY) shares sank 14% Thursday when the pharmaceutical …
Read More »Eli Lilly Weight-Loss Pill Trial Disappoints, Offsetting Solid Profit and Sales
:max_bytes(150000):strip_icc()/GettyImages-2228875514-0edc371647054064868bf3d68b3c636c.jpg "Eli Lilly Weight-Loss Pill Trial Disappoints, Offsetting Solid Profit and Sales")